;PMID: 10048151
;source_file_850.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..33] = [t:0..33]
;1)section:[e:39..87] = [t:39..87]
;2)sentence:[e:91..297] = [t:91..297]
;3)section:[e:301..352] = [t:301..352]
;4)section:[e:356..461] = [t:356..461]
;5)sentence:[e:465..640] = [t:465..640]
;6)sentence:[e:641..728] = [t:641..728]
;7)sentence:[e:729..927] = [t:729..927]
;8)sentence:[e:928..1028] = [t:928..1028]
;9)sentence:[e:1029..1294] = [t:1029..1294]
;10)sentence:[e:1295..1601] = [t:1295..1601]
;11)sentence:[e:1602..1795] = [t:1602..1795]
;12)sentence:[e:1796..2114] = [t:1796..2114]
;13)sentence:[e:2115..2445] = [t:2115..2445]
;14)sentence:[e:2447..2512] = [t:2447..2512]
;15)sentence:[e:2513..2679] = [t:2513..2679]
;16)sentence:[e:2680..2920] = [t:2680..2920]
;17)section:[e:2924..2969] = [t:2924..2969]

;section 0 Span:0..33
;Toxicol Sci. 1999 Jan;47(1):33-9.
(SEC
  (FRAG (NNP:[0..7] Toxicol) (NNP:[8..11] Sci) (.:[11..12] .) (CD:[13..17] 1999)
        (::[18..25] Jan;47-LRB-) (CD:[25..26] 1) (-RRB-:[26..27] -RRB-)
        (CD:[27..30] :33) (::[30..31] -) (CD:[31..33] 9.)))

;section 1 Span:39..87
;Erratum in:      Toxicol Sci 1999 Jul;50(1):153.
(SEC
  (FRAG (NNP:[39..46] Erratum) (IN:[47..49] in) (NNP:[49..50] :)
        (NNP:[56..63] Toxicol) (NNP:[64..67] Sci) (CD:[68..72] 1999)
        (.:[73..80] Jul;50-LRB-) (CD:[80..81] 1) (-RRB-:[81..82] -RRB-)
        (CD:[82..86] :153) (.:[86..87] .)))

;sentence 2 Span:91..297
;The effect of cotinine or cigarette smoke co-administration on the formation
;of  O6-methylguanine adducts in the lung and liver of A/J mice treated with 
;4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)
;[105..113]:substance:"cotinine"
;[117..132]:substance:"cigarette smoke"
;[172..188]:substance:"O6-methylguanine"
;[189..196]:substance:"adducts"
;[245..291]:substance:"4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone"
;[293..296]:substance:"NNK"
(SENT
  (NP-HLN
    (NP (DT:[91..94] The) (NN:[95..101] effect))
    (PP (IN:[102..104] of)
      (NP
        (NP (NN:[105..113] cotinine)
          (NML-1 (-NONE-:[113..113] *P*)))
        (CC:[114..116] or)
        (NP
          (NML (NN:[117..126] cigarette) (NN:[127..132] smoke))
          (NML-1 (AFX:[133..135] co) (HYPH:[135..136] -)
                 (NN:[136..150] administration)))))
    (PP (IN:[151..153] on)
      (NP
        (NP (DT:[154..157] the) (NN:[158..167] formation))
        (PP (IN:[168..170] of)
          (NP (NN:[172..188] O6-methylguanine) (NNS:[189..196] adducts)))))
    (PP-LOC (IN:[197..199] in)
      (NP
        (NP (DT:[200..203] the) (NN:[204..208] lung) (CC:[209..212] and)
            (NN:[213..218] liver))
        (PP (IN:[219..221] of)
          (NP
            (NP
              (NML (NN:[222..223] A) (SYM:[223..224] /) (NN:[224..225] J))
              (NNS:[226..230] mice))
            (VP (VBN:[231..238] treated)
              (NP (-NONE-:[238..238] *))
              (PP-CLR (IN:[239..243] with)
                (NP
                  (NP
                      (NN:[245..291] 4--LRB-methylnitrosamino-RRB--1--LRB-3-pyridyl-RRB--1-butanone))
                  (NP (-LRB-:[292..293] -LRB-) (NN:[293..296] NNK)
                      (-RRB-:[296..297] -RRB-)))))))))))

;section 3 Span:301..352
;Brown BG, Chang CJ, Ayres PH, Lee CK, Doolittle DJ.
(SEC
  (FRAG (NNP:[301..306] Brown) (NNP:[307..309] BG) (,:[309..310] ,)
        (NNP:[311..316] Chang) (NNP:[317..319] CJ) (,:[319..320] ,)
        (NNP:[321..326] Ayres) (NNP:[327..329] PH) (,:[329..330] ,)
        (NNP:[331..334] Lee) (NNP:[335..337] CK) (,:[337..338] ,)
        (NNP:[339..348] Doolittle) (NNP:[349..352] DJ.)))

;section 4 Span:356..461
;Research & Development Department, R. J. Reynolds Tobacco Co., Winston-Salem,
; North Carolina 27102, USA.
(SEC
  (FRAG (NNP:[356..364] Research) (NNP:[365..366] &)
        (NNP:[367..378] Development) (NNP:[379..389] Department)
        (,:[389..390] ,) (NNP:[391..393] R.) (NNP:[394..396] J.)
        (NNP:[397..405] Reynolds) (NNP:[406..413] Tobacco) (NNP:[414..417] Co.)
        (,:[417..418] ,) (NNP:[419..426] Winston) (::[426..427] -)
        (NNP:[427..432] Salem) (,:[432..433] ,) (NNP:[435..440] North)
        (NNP:[441..449] Carolina) (CD:[450..455] 27102) (,:[455..456] ,)
        (NNP:[457..460] USA) (.:[460..461] .)))

;sentence 5 Span:465..640
;4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), a tobacco-specific 
;nitrosamine, induces lung adenomas in A/J mice, following a single 
;intraperitoneal (i.p.) injection.
;[465..511]:substance:"4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone"
;[513..516]:substance:"NNK"
;[521..528]:substance:"tobacco"
;[539..550]:substance:"nitrosamine"
(SENT
  (S
    (NP-SBJ
      (NP
        (NP
            (NN:[465..511] 4--LRB-methylnitrosamino-RRB--1--LRB-3-pyridyl-RRB--1-butanone))
        (NP (-LRB-:[512..513] -LRB-) (NN:[513..516] NNK)
            (-RRB-:[516..517] -RRB-)))
      (,:[517..518] ,)
      (NP (DT:[519..520] a)
        (ADJP (NN:[521..528] tobacco) (HYPH:[528..529] -)
              (JJ:[529..537] specific))
        (NN:[539..550] nitrosamine)))
    (,:[550..551] ,)
    (VP (VBZ:[552..559] induces)
      (NP (NN:[560..564] lung) (NNS:[565..573] adenomas))
      (PP-LOC (IN:[574..576] in)
        (NP
          (NML (NN:[577..578] A) (SYM:[578..579] /) (NN:[579..580] J))
          (NNS:[581..585] mice)))
      (,:[585..586] ,)
      (S-MNR
        (NP-SBJ (-NONE-:[586..586] *))
        (VP (VBG:[587..596] following)
          (NP (DT:[597..598] a) (JJ:[599..605] single)
            (ADJP
              (ADJP (JJ:[607..622] intraperitoneal))
              (ADJP (-LRB-:[623..624] -LRB-) (JJ:[624..628] i.p.)
                    (-RRB-:[628..629] -RRB-)))
            (NN:[630..639] injection)))))
    (.:[639..640] .)))

;sentence 6 Span:641..728
;However, inhalation of tobacco smoke has not  induced or promoted tumors in
;these mice.
;[664..677]:substance:"tobacco smoke"
(SENT
  (S
    (ADVP (RB:[641..648] However))
    (,:[648..649] ,)
    (NP-SBJ
      (NP (NN:[650..660] inhalation))
      (PP (IN:[661..663] of)
        (NP (NN:[664..671] tobacco) (NN:[672..677] smoke))))
    (VP (VBZ:[678..681] has) (RB:[682..685] not)
      (VP (VBN:[687..694] induced) (CC:[695..697] or) (VBN:[698..706] promoted)
        (NP (NNS:[707..713] tumors))
        (PP-LOC (IN:[714..716] in)
          (NP (DT:[717..722] these) (NNS:[723..727] mice)))))
    (.:[727..728] .)))

;sentence 7 Span:729..927
;NNK-induced lung tumorigenesis is  thought to involve O6-methylguanine
;(O6MeG) formation, leading to GC-->AT  transitional mispairing and an
;activation of the K-ras proto-oncogene in the A/J  mouse.
;[729..732]:substance:"NNK"
;[783..799]:substance:"O6-methylguanine"
;[801..806]:substance:"O6MeG"
(SENT
  (S
    (NP-SBJ-1
      (ADJP (NN:[729..732] NNK) (HYPH:[732..733] -) (VBN:[733..740] induced))
      (NN:[741..745] lung) (NN:[746..759] tumorigenesis))
    (VP (VBZ:[760..762] is)
      (VP (VBN:[764..771] thought)
        (S
          (NP-SBJ-1 (-NONE-:[771..771] *))
          (VP (TO:[772..774] to)
            (VP (VB:[775..782] involve)
              (NP
                (NML
                  (NML (NN:[783..799] O6-methylguanine))
                  (NML (-LRB-:[800..801] -LRB-) (NN:[801..806] O6MeG)
                       (-RRB-:[806..807] -RRB-)))
                (NN:[808..817] formation))
              (,:[817..818] ,)
              (S-MNR
                (NP-SBJ (-NONE-:[818..818] *))
                (VP (VBG:[819..826] leading)
                  (PP-CLR (TO:[827..829] to)
                    (NP
                      (NP
                        (NML
                          (NML (NN:[830..832] GC))
                          (PP (SYM:[832..835] -->)
                            (NP (NN:[835..837] AT))))
                        (JJ:[839..851] transitional) (NN:[852..862] mispairing))
                      (CC:[863..866] and)
                      (NP
                        (NP (DT:[867..869] an) (NN:[870..880] activation))
                        (PP (IN:[881..883] of)
                          (NP (DT:[884..887] the) (NN:[888..893] K-ras)
                              (AFX:[894..899] proto) (HYPH:[899..900] -)
                              (NN:[900..908] oncogene)))
                        (PP-LOC (IN:[909..911] in)
                          (NP (DT:[912..915] the)
                            (NML (NN:[916..917] A) (SYM:[917..918] /)
                                 (NN:[918..919] J))
                            (NN:[921..926] mouse)))))))))))))
    (.:[926..927] .)))

;sentence 8 Span:928..1028
;NNK can be metabolized by several different cytochromes P450, resulting  in a
;number of metabolites.
;[928..931]:substance:"NNK"
;[972..988]:cyp450:"cytochromes P450"
;[1016..1027]:substance:"metabolites"
(SENT
  (S
    (NP-SBJ-1 (NN:[928..931] NNK))
    (VP (MD:[932..935] can)
      (VP (VB:[936..938] be)
        (VP (VBN:[939..950] metabolized)
          (NP-1 (-NONE-:[950..950] *))
          (PP (IN:[951..953] by)
            (NP-LGS (JJ:[954..961] several) (JJ:[962..971] different)
               (NNS:[972..983] cytochromes) (NN:[984..988] P450)))
          (,:[988..989] ,)
          (S-MNR
            (NP-SBJ (-NONE-:[989..989] *))
            (VP (VBG:[990..999] resulting)
              (PP-CLR (IN:[1001..1003] in)
                (NP
                  (NP (DT:[1004..1005] a) (NN:[1006..1012] number))
                  (PP (IN:[1013..1015] of)
                    (NP (NNS:[1016..1027] metabolites))))))))))
    (.:[1027..1028] .)))

;sentence 9 Span:1029..1294
;Formation of the promutagenic DNA adduct O6MeG is  believed to require
;metabolic activation of NNK by cytochrome P450-mediated  alpha-hydroxylation
;of the methylene group adjacent to the N-nitroso nitrogen to  yield the
;unstable intermediate, methanediazohydroxide.
;[1059..1062]:substance:"DNA"
;[1063..1069]:substance:"adduct"
;[1070..1075]:substance:"O6MeG"
;[1124..1127]:substance:"NNK"
;[1131..1146]:cyp450:"cytochrome P450"
;[1258..1270]:substance:"intermediate"
;[1272..1293]:substance:"methanediazohydroxide"
(SENT
  (S
    (NP-SBJ-1
      (NP (NN:[1029..1038] Formation))
      (PP (IN:[1039..1041] of)
        (NP
          (NP (DT:[1042..1045] the) (JJ:[1046..1058] promutagenic)
              (NN:[1059..1062] DNA) (NN:[1063..1069] adduct))
          (NP (NN:[1070..1075] O6MeG)))))
    (VP (VBZ:[1076..1078] is)
      (VP (VBN:[1080..1088] believed)
        (S
          (NP-SBJ-1 (-NONE-:[1088..1088] *))
          (VP (TO:[1089..1091] to)
            (VP (VB:[1092..1099] require)
              (NP
                (NP (JJ:[1100..1109] metabolic) (NN:[1110..1120] activation))
                (PP (IN:[1121..1123] of)
                  (NP (NN:[1124..1127] NNK)))
                (PP (IN:[1128..1130] by)
                  (NP
                    (NP
                      (ADJP
                        (NML (NN:[1131..1141] cytochrome) (NN:[1142..1146] P450))
                        (HYPH:[1146..1147] -) (VBN:[1147..1155] mediated))
                      (NN:[1157..1176] alpha-hydroxylation))
                    (PP (IN:[1177..1179] of)
                      (NP
                        (NP (DT:[1180..1183] the) (NN:[1184..1193] methylene)
                            (NN:[1194..1199] group))
                        (ADJP (JJ:[1200..1208] adjacent)
                          (PP (TO:[1209..1211] to)
                            (NP (DT:[1212..1215] the)
                                (NN:[1216..1225] N-nitroso)
                                (NN:[1226..1234] nitrogen)))))))))
              (S-PRP
                (NP-SBJ (-NONE-:[1234..1234] *))
                (VP (TO:[1235..1237] to)
                  (VP (VB:[1239..1244] yield)
                    (NP
                      (NP (DT:[1245..1248] the) (JJ:[1249..1257] unstable)
                          (NN:[1258..1270] intermediate))
                      (,:[1270..1271] ,)
                      (NP (NN:[1272..1293] methanediazohydroxide)))))))))))
    (.:[1293..1294] .)))

;sentence 10 Span:1295..1601
;Nicotine, cotinine (the  major metabolite of nicotine), and aqueous cigarette
;tar extract (ACTE) have all  been shown to effectively inhibit metabolic
;activation of NNK to its mutagenic  form, most likely due to competitive
;inhibition of the cytochrome P450 enzymes  involved in alpha-hydroxylation of
;NNK.
;[1295..1303]:substance:"Nicotine"
;[1305..1313]:substance:"cotinine"
;[1326..1336]:substance:"metabolite"
;[1340..1348]:substance:"nicotine"
;[1355..1384]:substance:"aqueous cigarette tar extract"
;[1386..1390]:substance:"ACTE"
;[1460..1463]:substance:"NNK"
;[1537..1560]:cyp450:"cytochrome P450 enzymes"
;[1597..1600]:substance:"NNK"
(SENT
  (S
    (NP-SBJ-1
      (NP (NN:[1295..1303] Nicotine))
      (,:[1303..1304] ,)
      (NP (NN:[1305..1313] cotinine)
        (PRN (-LRB-:[1314..1315] -LRB-)
          (NP
            (NP (DT:[1315..1318] the) (JJ:[1320..1325] major)
                (NN:[1326..1336] metabolite))
            (PP (IN:[1337..1339] of)
              (NP (NN:[1340..1348] nicotine))))
          (-RRB-:[1348..1349] -RRB-)))
      (,:[1349..1350] ,) (CC:[1351..1354] and)
      (NP
        (NP (JJ:[1355..1362] aqueous)
          (NML (NN:[1363..1372] cigarette) (NN:[1373..1376] tar))
          (NN:[1377..1384] extract))
        (NP (-LRB-:[1385..1386] -LRB-) (NN:[1386..1390] ACTE)
            (-RRB-:[1390..1391] -RRB-))))
    (VP (VBP:[1392..1396] have) (DT:[1397..1400] all)
      (VP (VBN:[1402..1406] been)
        (VP (VBN:[1407..1412] shown)
          (S
            (NP-SBJ-1 (-NONE-:[1412..1412] *))
            (VP (TO:[1413..1415] to)
              (VP
                (ADVP (RB:[1416..1427] effectively))
                (VB:[1428..1435] inhibit)
                (NP
                  (NP (JJ:[1436..1445] metabolic) (NN:[1446..1456] activation))
                  (PP (IN:[1457..1459] of)
                    (NP (NN:[1460..1463] NNK)))
                  (PP (TO:[1464..1466] to)
                    (NP (PRP$:[1467..1470] its) (JJ:[1471..1480] mutagenic)
                        (NN:[1482..1486] form))))
                (,:[1486..1487] ,)
                (PP
                  (ADVP (RBS:[1488..1492] most) (JJ:[1493..1499] likely))
                  (JJ:[1500..1503] due)
                  (PP (TO:[1504..1506] to)
                    (NP
                      (NP (JJ:[1507..1518] competitive)
                          (NN:[1519..1529] inhibition))
                      (PP (IN:[1530..1532] of)
                        (NP
                          (NP (DT:[1533..1536] the)
                             (NN:[1537..1547] cytochrome) (NN:[1548..1552] P450)
                             (NNS:[1553..1560] enzymes))
                          (VP (VBN:[1562..1570] involved)
                            (NP (-NONE-:[1570..1570] *))
                            (PP-CLR (IN:[1571..1573] in)
                              (NP
                                (NP (NN:[1574..1593] alpha-hydroxylation))
                                (PP (IN:[1594..1596] of)
                                  (NP (NN:[1597..1600] NNK)))))))))))))))))
    (.:[1600..1601] .)))

;sentence 11 Span:1602..1795
;The objective of the current study was  to monitor the effects of cotinine
;and cigarette smoke (CS) on the formation of  O6MeG in target tissues of mice
;during the acute phase of NNK treatment.
;[1668..1676]:substance:"cotinine"
;[1681..1696]:substance:"cigarette smoke"
;[1698..1700]:substance:"CS"
;[1723..1728]:substance:"O6MeG"
;[1781..1784]:substance:"NNK"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[1602..1605] The) (NN:[1606..1615] objective))
      (PP (IN:[1616..1618] of)
        (NP (DT:[1619..1622] the) (JJ:[1623..1630] current)
            (NN:[1631..1636] study))))
    (VP (VBD:[1637..1640] was)
      (S-PRP-PRD
        (NP-SBJ (-NONE-:[1640..1640] *))
        (VP (TO:[1642..1644] to)
          (VP (VB:[1645..1652] monitor)
            (NP
              (NP (DT:[1653..1656] the) (NNS:[1657..1664] effects))
              (PP (IN:[1665..1667] of)
                (NP
                  (NP (NN:[1668..1676] cotinine))
                  (CC:[1677..1680] and)
                  (NP
                    (NP (NN:[1681..1690] cigarette) (NN:[1691..1696] smoke))
                    (NP (-LRB-:[1697..1698] -LRB-) (NN:[1698..1700] CS)
                        (-RRB-:[1700..1701] -RRB-)))))
              (PP (IN:[1702..1704] on)
                (NP
                  (NP (DT:[1705..1708] the) (NN:[1709..1718] formation))
                  (PP (IN:[1719..1721] of)
                    (NP (NN:[1723..1728] O6MeG)))
                  (PP-LOC (IN:[1729..1731] in)
                    (NP
                      (NP (NN:[1732..1738] target) (NNS:[1739..1746] tissues))
                      (PP (IN:[1747..1749] of)
                        (NP (NNS:[1750..1754] mice)))))
                  (PP-TMP (IN:[1755..1761] during)
                    (NP
                      (NP (DT:[1762..1765] the) (JJ:[1766..1771] acute)
                          (NN:[1772..1777] phase))
                      (PP (IN:[1778..1780] of)
                        (NP (NN:[1781..1784] NNK) (NN:[1785..1794] treatment))))))))))))
    (.:[1794..1795] .)))

;sentence 12 Span:1796..2114
;To test  the effect of cotinine, mature female A/J mice received a single
;intraperitoneal  injection of NNK (0, 2.5, 5, 7.5, or 10 mumole/mouse) with
;cotinine administered  at a total dose of 50 mumole/mouse in 3 separate i.p.
;injections, administered  30 min before, immediately after, and 30 min after
;NNK treatment.
;[1819..1827]:substance:"cotinine"
;[1900..1903]:substance:"NNK"
;[1905..1906]:quantitative-value:"0"
;[1908..1911]:quantitative-value:"2.5"
;[1913..1914]:quantitative-value:"5"
;[1916..1919]:quantitative-value:"7.5"
;[1924..1926]:quantitative-value:"10"
;[1927..1939]:quantitative-units:"mumole/mouse"
;[1946..1954]:substance:"cotinine"
;[1988..1990]:quantitative-value:"50"
;[1991..2003]:quantitative-units:"mumole/mouse"
;[2007..2008]:quantitative-value:"3"
;[2049..2051]:quantitative-value:"30"
;[2052..2055]:quantitative-units:"min"
;[2087..2089]:quantitative-value:"30"
;[2090..2093]:quantitative-units:"min"
;[2100..2103]:substance:"NNK"
(SENT
  (S
    (S-PRP
      (NP-SBJ (-NONE-:[1796..1796] *))
      (VP (TO:[1796..1798] To)
        (VP (VB:[1799..1803] test)
          (NP
            (NP (DT:[1805..1808] the) (NN:[1809..1815] effect))
            (PP (IN:[1816..1818] of)
              (NP (NN:[1819..1827] cotinine)))))))
    (,:[1827..1828] ,)
    (NP-SBJ (JJ:[1829..1835] mature) (JJ:[1836..1842] female)
      (NML (NN:[1843..1844] A) (SYM:[1844..1845] /) (NN:[1845..1846] J))
      (NNS:[1847..1851] mice))
    (VP (VBD:[1852..1860] received)
      (NP
        (NP (DT:[1861..1862] a) (JJ:[1863..1869] single)
            (JJ:[1870..1885] intraperitoneal) (NN:[1887..1896] injection))
        (PP (IN:[1897..1899] of)
          (NP (NN:[1900..1903] NNK)))
        (PRN (-LRB-:[1904..1905] -LRB-)
          (NP
            (NP
              (NP (CD:[1905..1906] 0)
                (NML-2 (-NONE-:[1906..1906] *P*)))
              (PP-3 (-NONE-:[1906..1906] *P*)))
            (,:[1906..1907] ,)
            (NP
              (NP (CD:[1908..1911] 2.5)
                (NML-2 (-NONE-:[1911..1911] *P*)))
              (PP-3 (-NONE-:[1911..1911] *P*)))
            (,:[1911..1912] ,)
            (NP
              (NP (CD:[1913..1914] 5)
                (NML-2 (-NONE-:[1914..1914] *P*)))
              (PP-3 (-NONE-:[1914..1914] *P*)))
            (,:[1914..1915] ,)
            (NP
              (NP (CD:[1916..1919] 7.5)
                (NML-2 (-NONE-:[1919..1919] *P*)))
              (PP-3 (-NONE-:[1919..1919] *P*)))
            (,:[1919..1920] ,) (CC:[1921..1923] or)
            (NP
              (NP (CD:[1924..1926] 10)
                (NML-2 (NN:[1927..1933] mumole)))
              (PP-3 (SYM:[1933..1934] /)
                (NP (NN:[1934..1939] mouse)))))
          (-RRB-:[1939..1940] -RRB-))
        (PP (IN:[1941..1945] with)
          (NP
            (NP (NN:[1946..1954] cotinine))
            (VP (VBN:[1955..1967] administered)
              (NP (-NONE-:[1967..1967] *))
              (PP (IN:[1969..1971] at)
                (NP
                  (NP (DT:[1972..1973] a) (JJ:[1974..1979] total)
                      (NN:[1980..1984] dose))
                  (PP (IN:[1985..1987] of)
                    (NP
                      (NP (CD:[1988..1990] 50) (NN:[1991..1997] mumole))
                      (PP (SYM:[1997..1998] /)
                        (NP (NN:[1998..2003] mouse)))))))
              (PP (IN:[2004..2006] in)
                (NP
                  (NP (CD:[2007..2008] 3) (JJ:[2009..2017] separate)
                      (JJ:[2018..2022] i.p.) (NNS:[2023..2033] injections))
                  (,:[2033..2034] ,)
                  (VP (VBN:[2035..2047] administered)
                    (NP (-NONE-:[2047..2047] *))
                    (PP-TMP
                      (PP
                        (NP-ADV (CD:[2049..2051] 30) (NN:[2052..2055] min))
                        (IN:[2056..2062] before)
                        (NP-1 (-NONE-:[2062..2062] *RNR*)))
                      (,:[2062..2063] ,)
                      (PP
                        (ADVP (RB:[2064..2075] immediately))
                        (IN:[2076..2081] after)
                        (NP-1 (-NONE-:[2081..2081] *RNR*)))
                      (,:[2081..2082] ,) (CC:[2083..2086] and)
                      (PP
                        (NP-ADV (CD:[2087..2089] 30) (NN:[2090..2093] min))
                        (IN:[2094..2099] after)
                        (NP-1 (-NONE-:[2099..2099] *RNR*)))
                      (NP-1 (NN:[2100..2103] NNK) (NN:[2104..2113] treatment)))))))))))
    (.:[2113..2114] .)))

;sentence 13 Span:2115..2445
;To test the  effect of whole smoke exposure on NNK-related O6MeG formation,
;mice were exposed  to smoke generated from Kentucky 1R4F reference cigarettes
;at 0, 0.4, 0.6, or  0.8 mg wet total particulate matter/liter (WTPM/L) for 2
;h, with a single i.p.  injection of NNK (0, 3.75, or 7.5 mumole/mouse) midway
;through the exposure.
;[2144..2149]:substance:"smoke"
;[2162..2165]:substance:"NNK"
;[2174..2179]:substance:"O6MeG"
;[2213..2218]:substance:"smoke"
;[2272..2273]:quantitative-value:"0"
;[2275..2278]:quantitative-value:"0.4"
;[2280..2283]:quantitative-value:"0.6"
;[2289..2292]:quantitative-value:"0.8"
;[2293..2295]:quantitative-units:"mg"
;[2296..2330]:quantitative-units:"wet total particulate matter/liter"
;[2332..2338]:quantitative-units:"WTPM/L"
;[2344..2345]:quantitative-value:"2"
;[2346..2347]:quantitative-units:"h"
;[2382..2385]:substance:"NNK"
;[2387..2388]:quantitative-value:"0"
;[2390..2394]:quantitative-value:"3.75"
;[2399..2402]:quantitative-value:"7.5"
;[2403..2415]:quantitative-units:"mumole/mouse"
(SENT
  (S
    (S-PRP
      (NP-SBJ (-NONE-:[2115..2115] *))
      (VP (TO:[2115..2117] To)
        (VP (VB:[2118..2122] test)
          (NP
            (NP (DT:[2123..2126] the) (NN:[2128..2134] effect))
            (PP (IN:[2135..2137] of)
              (NP
                (NML (JJ:[2138..2143] whole) (NN:[2144..2149] smoke))
                (NN:[2150..2158] exposure)))
            (PP (IN:[2159..2161] on)
              (NP
                (ADJP (NN:[2162..2165] NNK) (HYPH:[2165..2166] -)
                      (VBN:[2166..2173] related))
                (NN:[2174..2179] O6MeG) (NN:[2180..2189] formation)))))))
    (,:[2189..2190] ,)
    (NP-SBJ-3 (NNS:[2191..2195] mice))
    (VP (VBD:[2196..2200] were)
      (VP (VBN:[2201..2208] exposed)
        (NP-3 (-NONE-:[2208..2208] *))
        (PP-CLR (TO:[2210..2212] to)
          (NP
            (NP (NN:[2213..2218] smoke))
            (VP (VBN:[2219..2228] generated)
              (NP (-NONE-:[2228..2228] *))
              (PP (IN:[2229..2233] from)
                (NP (NNP:[2234..2242] Kentucky) (NN:[2243..2247] 1R4F)
                    (NN:[2248..2257] reference) (NNS:[2258..2268] cigarettes))))))
        (PP (IN:[2269..2271] at)
          (NP
            (NP
              (NP (CD:[2272..2273] 0)
                (NML-2 (-NONE-:[2273..2273] *P*)))
              (PP-4 (-NONE-:[2273..2273] *P*)))
            (,:[2273..2274] ,)
            (NP
              (NP (CD:[2275..2278] 0.4)
                (NML-2 (-NONE-:[2278..2278] *P*)))
              (PP-4 (-NONE-:[2278..2278] *P*)))
            (,:[2278..2279] ,)
            (NP
              (NP (CD:[2280..2283] 0.6)
                (NML-2 (-NONE-:[2283..2283] *P*)))
              (PP-4 (-NONE-:[2283..2283] *P*)))
            (,:[2283..2284] ,) (CC:[2285..2287] or)
            (NP
              (NP
                (NP (CD:[2289..2292] 0.8) (NN:[2293..2295] mg)
                  (NML-2 (JJ:[2296..2299] wet) (JJ:[2300..2305] total)
                         (NN:[2306..2317] particulate) (NN:[2318..2324] matter)))
                (PP-4 (SYM:[2324..2325] /)
                  (NP (NN:[2325..2330] liter))))
              (PRN (-LRB-:[2331..2332] -LRB-)
                (NP
                  (NP (NN:[2332..2336] WTPM))
                  (PP (SYM:[2336..2337] /)
                    (NP (NN:[2337..2338] L))))
                (-RRB-:[2338..2339] -RRB-)))))
        (PP-TMP (IN:[2340..2343] for)
          (NP (CD:[2344..2345] 2) (NN:[2346..2347] h)))
        (,:[2347..2348] ,)
        (PP (IN:[2349..2353] with)
          (NP
            (NP
              (NP (DT:[2354..2355] a) (JJ:[2356..2362] single)
                  (JJ:[2363..2367] i.p.) (NN:[2369..2378] injection))
              (PP (IN:[2379..2381] of)
                (NP (NN:[2382..2385] NNK))))
            (PRN (-LRB-:[2386..2387] -LRB-)
              (NP
                (NP
                  (NP (CD:[2387..2388] 0)
                    (NML-1 (-NONE-:[2388..2388] *P*)))
                  (PP-5 (-NONE-:[2388..2388] *P*)))
                (,:[2388..2389] ,)
                (NP
                  (NP (CD:[2390..2394] 3.75)
                    (NML-1 (-NONE-:[2394..2394] *P*)))
                  (PP-5 (-NONE-:[2394..2394] *P*)))
                (,:[2394..2395] ,) (CC:[2396..2398] or)
                (NP
                  (NP (CD:[2399..2402] 7.5)
                    (NML-1 (NN:[2403..2409] mumole)))
                  (PP-5 (SYM:[2409..2410] /) (NN:[2410..2415] mouse))))
              (-RRB-:[2415..2416] -RRB-))
            (ADJP-TMP (RB:[2417..2423] midway)
              (PP (IN:[2424..2431] through)
                (NP (DT:[2432..2435] the) (NN:[2436..2444] exposure))))))))
    (.:[2444..2445] .)))

;sentence 14 Span:2447..2512
;Cigarette smoke alone failed to yield detectable levels of O6MeG.
;[2447..2462]:substance:"Cigarette smoke"
;[2506..2511]:substance:"O6MeG"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[2447..2456] Cigarette) (NN:[2457..2462] smoke))
      (ADJP (RB:[2463..2468] alone)))
    (VP (VBD:[2469..2475] failed)
      (S
        (NP-SBJ (-NONE-:[2475..2475] *))
        (VP (TO:[2476..2478] to)
          (VP (VB:[2479..2484] yield)
            (NP
              (NP (JJ:[2485..2495] detectable) (NNS:[2496..2502] levels))
              (PP (IN:[2503..2505] of)
                (NP (NN:[2506..2511] O6MeG))))))))
    (.:[2511..2512] .)))

;sentence 15 Span:2513..2679
;The number of  O6MeG adducts following i.p. injection of NNK was
;significantly (p < 0.05)  reduced in both lung and liver by cotinine and by
;cigarette smoke exposure.
;[2528..2533]:substance:"O6MeG"
;[2534..2541]:substance:"adducts"
;[2570..2573]:substance:"NNK"
;[2593..2594]:quantitative-name:"p"
;[2597..2601]:quantitative-value:"0.05"
;[2638..2646]:substance:"cotinine"
;[2654..2669]:substance:"cigarette smoke"
(SENT
  (S
    (NP-SBJ-1
      (NP
        (NP (DT:[2513..2516] The) (NN:[2517..2523] number))
        (PP (IN:[2524..2526] of)
          (NP (NN:[2528..2533] O6MeG) (NNS:[2534..2541] adducts))))
      (VP (VBG:[2542..2551] following)
        (NP
          (NP (JJ:[2552..2556] i.p.) (NN:[2557..2566] injection))
          (PP (IN:[2567..2569] of)
            (NP (NN:[2570..2573] NNK))))))
    (VP (VBD:[2574..2577] was)
      (VP
        (ADVP (RB:[2578..2591] significantly)
          (PRN (-LRB-:[2592..2593] -LRB-)
            (S
              (NP-SBJ (NN:[2593..2594] p))
              (VP (SYM:[2595..2596] <)
                (NP (CD:[2597..2601] 0.05))))
            (-RRB-:[2601..2602] -RRB-)))
        (VBN:[2604..2611] reduced)
        (NP-1 (-NONE-:[2611..2611] *))
        (PP-LOC (IN:[2612..2614] in)
          (NP (CC:[2615..2619] both) (NN:[2620..2624] lung)
              (CC:[2625..2628] and) (NN:[2629..2634] liver)))
        (PP
          (PP (IN:[2635..2637] by)
            (NP-LGS (NN:[2638..2646] cotinine)))
          (CC:[2647..2650] and)
          (PP (IN:[2651..2653] by)
            (NP-LGS
              (NML (NN:[2654..2663] cigarette) (NN:[2664..2669] smoke))
              (NN:[2670..2678] exposure))))))
    (.:[2678..2679] .)))

;sentence 16 Span:2680..2920
;Our  results demonstrate that NNK-induced O6MeG DNA adducts in A/J mice are 
;significantly reduced when NNK is administered together with either cotinine,
; the major metabolite of nicotine, or the parental complex mixture, cigarette
; smoke.
;[2710..2713]:substance:"NNK"
;[2722..2727]:substance:"O6MeG"
;[2728..2731]:substance:"DNA"
;[2732..2739]:substance:"adducts"
;[2784..2787]:substance:"NNK"
;[2825..2833]:substance:"cotinine"
;[2846..2856]:substance:"metabolite"
;[2860..2868]:substance:"nicotine"
;[2886..2901]:substance:"complex mixture"
;[2903..2919]:substance:"cigarette  smoke"
(SENT
  (S
    (NP-SBJ (PRP$:[2680..2683] Our) (NNS:[2685..2692] results))
    (VP (VBP:[2693..2704] demonstrate)
      (SBAR (IN:[2705..2709] that)
        (S
          (NP-SBJ-1
            (NP
              (NML
                (ADJP (NN:[2710..2713] NNK) (HYPH:[2713..2714] -)
                      (VBN:[2714..2721] induced))
                (NN:[2722..2727] O6MeG))
              (NN:[2728..2731] DNA) (NNS:[2732..2739] adducts))
            (PP (IN:[2740..2742] in)
              (NP
                (NML (NN:[2743..2744] A) (SYM:[2744..2745] /)
                     (NN:[2745..2746] J))
                (NNS:[2747..2751] mice))))
          (VP (VBP:[2752..2755] are)
            (ADVP (RB:[2757..2770] significantly))
            (VP (VBN:[2771..2778] reduced)
              (NP-1 (-NONE-:[2778..2778] *))
              (SBAR-ADV (WRB:[2779..2783] when)
                (S
                  (NP-SBJ-2 (NN:[2784..2787] NNK))
                  (VP (VBZ:[2788..2790] is)
                    (VP (VBN:[2791..2803] administered)
                      (NP-2 (-NONE-:[2803..2803] *))
                      (PP
                        (ADVP (RB:[2804..2812] together))
                        (IN:[2813..2817] with)
                        (NP (CC:[2818..2824] either)
                          (NP
                            (NP (NN:[2825..2833] cotinine))
                            (,:[2833..2834] ,)
                            (NP
                              (NP (DT:[2836..2839] the) (JJ:[2840..2845] major)
                                  (NN:[2846..2856] metabolite))
                              (PP (IN:[2857..2859] of)
                                (NP (NN:[2860..2868] nicotine)))))
                          (,:[2868..2869] ,) (CC:[2870..2872] or)
                          (NP
                            (NP (DT:[2873..2876] the) (JJ:[2877..2885] parental)
                               (NN:[2886..2893] complex)
                               (NN:[2894..2901] mixture))
                            (,:[2901..2902] ,)
                            (NP (NN:[2903..2912] cigarette)
                                (NN:[2914..2919] smoke))))))))))))))
    (.:[2919..2920] .)))

;section 17 Span:2924..2969
;PMID: 10048151 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[2924..2928] PMID) (::[2928..2929] :) (CD:[2930..2938] 10048151)
        (NN:[2939..2940] -LSB-) (NNP:[2940..2946] PubMed) (::[2947..2948] -)
        (NN:[2949..2956] indexed) (IN:[2957..2960] for)
        (NNP:[2961..2969] MEDLINE-RSB-)))
